307 related articles for article (PubMed ID: 36099094)
1. Combination Treatment Using Pyruvate Kinase M2 Inhibitors for the Sensitization of High Density Triple-negative Breast Cancer Cells.
Lee JS; Oh Y; Lee JS; Park JH; Shin JK; Han JH; Kim HS; Yoon S
In Vivo; 2022; 36(5):2105-2115. PubMed ID: 36099094
[TBL] [Abstract][Full Text] [Related]
2. PKM2 Is Overexpressed in Glioma Tissues, and Its Inhibition Highly Increases Late Apoptosis in U87MG Cells With Low-density Specificity.
Park JH; Lee JS; Oh Y; Lee JS; Park HE; Lee H; Park YS; Kyung SY; Kim HS; Yoon S
In Vivo; 2022; 36(2):694-703. PubMed ID: 35241524
[TBL] [Abstract][Full Text] [Related]
3. Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling.
Chen Y; Chen ZY; Chen L; Zhang JY; Fu LY; Tao L; Zhang Y; Hu XX; Shen XC
Biochem Pharmacol; 2019 Aug; 166():33-45. PubMed ID: 31071331
[TBL] [Abstract][Full Text] [Related]
4. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
[TBL] [Abstract][Full Text] [Related]
5. Identification of Gliotoxin isolated from marine fungus as a new pyruvate kinase M2 inhibitor.
Tang W; Liu ZL; Mai XY; Qi X; Li DH; Gu QQ; Li J
Biochem Biophys Res Commun; 2020 Jul; 528(3):594-600. PubMed ID: 32507600
[TBL] [Abstract][Full Text] [Related]
6. Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway.
Dai Y; Liu Y; Li J; Jin M; Yang H; Huang G
Bioengineered; 2022 May; 13(5):13906-13918. PubMed ID: 35706397
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel naphthoquinone derivatives as inhibitors of the tumor cell specific M2 isoform of pyruvate kinase.
Ning X; Qi H; Li R; Li Y; Jin Y; McNutt MA; Liu J; Yin Y
Eur J Med Chem; 2017 Sep; 138():343-352. PubMed ID: 28688274
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Pyruvate Kinase M2 Markedly Reduces Chemoresistance of Advanced Bladder Cancer to Cisplatin.
Wang X; Zhang F; Wu XR
Sci Rep; 2017 Apr; 7():45983. PubMed ID: 28378811
[TBL] [Abstract][Full Text] [Related]
9. Shikonin is a novel and selective IMPDH2 inhibitor that target triple-negative breast cancer.
Wang W; Wu Y; Chen S; Liu X; He J; Wang S; Lu W; Tang Y; Huang J
Phytother Res; 2021 Jan; 35(1):463-476. PubMed ID: 32779300
[TBL] [Abstract][Full Text] [Related]
10. A modified natural small molecule inhibits triple-negative breast cancer growth by interacting with Tubb3.
Han H; Yang M; Wen Z; Wang X; Lai X; Zhang Y; Fang R; Yin T; Yang X; Wang X; Zhao Q; Qi J; Chen H; Lin H; Yang Y
Phytomedicine; 2024 Apr; 126():154894. PubMed ID: 38377719
[TBL] [Abstract][Full Text] [Related]
11. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2.
Chen J; Xie J; Jiang Z; Wang B; Wang Y; Hu X
Oncogene; 2011 Oct; 30(42):4297-306. PubMed ID: 21516121
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and antitumor activity of novel 2, 3-didithiocarbamate substituted naphthoquinones as inhibitors of pyruvate kinase M2 isoform.
Ning X; Qi H; Li R; Jin Y; McNutt MA; Yin Y
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):126-129. PubMed ID: 29185365
[TBL] [Abstract][Full Text] [Related]
13. RIP1K and RIP3K provoked by shikonin induce cell cycle arrest in the triple negative breast cancer cell line, MDA-MB-468: necroptosis as a desperate programmed suicide pathway.
Shahsavari Z; Karami-Tehrani F; Salami S; Ghasemzadeh M
Tumour Biol; 2016 Apr; 37(4):4479-91. PubMed ID: 26496737
[TBL] [Abstract][Full Text] [Related]
14. Platinum complexes inhibit HER-2 enriched and triple-negative breast cancer cells metabolism to suppress growth, stemness and migration by targeting PKM/LDHA and CCND1/BCL2/ATG3 signaling pathways.
Bai X; Ali A; Lv Z; Wang N; Zhao X; Hao H; Zhang Y; Rahman FU
Eur J Med Chem; 2021 Nov; 224():113689. PubMed ID: 34293698
[TBL] [Abstract][Full Text] [Related]
15. EGFR and MEK Blockade in Triple Negative Breast Cancer Cells.
Maiello MR; D'Alessio A; Bevilacqua S; Gallo M; Normanno N; De Luca A
J Cell Biochem; 2015 Dec; 116(12):2778-85. PubMed ID: 25959272
[TBL] [Abstract][Full Text] [Related]
16. Anticancer Effects of Fucoxanthin through Cell Cycle Arrest, Apoptosis Induction, and Angiogenesis Inhibition in Triple-Negative Breast Cancer Cells.
Ahmed SA; Mendonca P; Messeha SS; Soliman KFA
Molecules; 2023 Sep; 28(18):. PubMed ID: 37764312
[TBL] [Abstract][Full Text] [Related]
17. Sensitizing the therapeutic efficacy of taxol with shikonin in human breast cancer cells.
Li W; Liu J; Jackson K; Shi R; Zhao Y
PLoS One; 2014; 9(4):e94079. PubMed ID: 24710512
[TBL] [Abstract][Full Text] [Related]
18. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
[TBL] [Abstract][Full Text] [Related]
19. Shikonin Inhibits Tumor Growth in Mice by Suppressing Pyruvate Kinase M2-mediated Aerobic Glycolysis.
Zhao X; Zhu Y; Hu J; Jiang L; Li L; Jia S; Zen K
Sci Rep; 2018 Sep; 8(1):14517. PubMed ID: 30266938
[TBL] [Abstract][Full Text] [Related]
20.
Rasul A; Riaz A; Wei W; Sarfraz I; Hassan M; Li J; Asif F; Adem Ş; Bukhari SA; Asrar M; Li X
Biomed Res Int; 2021; 2021():5514669. PubMed ID: 34136566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
